top of page

Trump-Xi Summit: The Definitive Shift from Trade War to a Clash Over Regulatory Sovereignty - A Brief Analysis

The upcoming summit scheduled for May 14–15, 2026, between President Donald Trump and President Xi Jinping in Beijing marks a critical turning point: the definitive shift from a trade dispute based on commodity flows to an unprecedented jurisdictional and regulatory conflict. At the core of the contention are no longer just trade balances, but the very sovereignty of the laws governing multinational companies operating across borders, in a context where China's strengthening of its national security regulatory framework is mirrored by the aggressive tariff maneuvers of the U.S. administration.


On October 30 of last year, a scene from the meeting between U.S. President Donald Trump (left) and Chinese President Xi Jinping in Busan. /Reuters-Yonhap
On October 30 of last year, a scene from the meeting between U.S. President Donald Trump (left) and Chinese President Xi Jinping in Busan. /Reuters-Yonhap

The Escalation of the "Blocking Statute" and the Role of the Chinese Ministry of Commerce

Beijing's legal architecture has undergone a decisive acceleration with the activation of regimes designed to counter foreign extraterritorial jurisdiction. A fundamental breaking point is represented by Announcement No. 21 of May 2, 2026, through which the Ministry of Commerce (MOFCOM) officially prohibited compliance with U.S. oil-related sanctions imposed on five Chinese petrochemical companies. These sanctions had been established by the United States via Executive Orders 13902 and 13846 and the inclusion in the Specially Designated Nationals List (SDN List).

From a legal perspective, this move transforms the so-called Chinese "blocking statute" — formally titled Rules on Counteracting Unjustified Extraterritorial Application of Foreign Legislation and Other Measures — from a theoretical tool into an actively enforced legal mechanism. The Ministry of Commerce (MOFCOM) does not merely prohibit the recognition of asset freezes imposed by the Office of Foreign Assets Control (OFAC); it exposes multinationals to direct civil liability in China. Companies following American restrictions can be sued to compensate for damages caused to local counterparts. This shift poses a fundamental question for the summit: whose law governs a multinational operating in both markets?


The Geofinancial Response and the Crackdown on "Singapore-washing"

To complete China’s regulatory lockdown, decrees from the State Council and the National Development and Reform Commission (NDRC) have been implemented. Decree No. 834 (April 7, 2026) established Article 13, which effectively criminalizes the collection of supply chain data, preventing independent Environmental, Social, and Governance (ESG) audits required by Western regulations. Simultaneously, Decree No. 835 (April 13, 2026) strengthened the right to claim damages against those applying foreign sanctions.

In this climate, the National Development and Reform Commission (NDRC), on April 24, 2026, issued directives to block the flow of American capital into tech startups (cases such as Moonshot AI and StepFun), responding symmetrically to the acquisition of the startup Manus by Meta. Beijing is formally terminating the phenomenon of "Singapore-washing": Chinese jurisdiction follows the technology and talent regardless of the formal foreign legal headquarters, converting supply chain diversification into a high-stakes legal risk.


Targeted U.S. Tariff Arsenal Against China

The Trump administration has responded by activating a network of tariffs and restrictions specifically aimed at hitting strategic nodes of Chinese production, using them as leverage ahead of the meeting:

  • Section 232 on Semiconductors and Technology (January 15, 2026): Imposition of a 25% duty on semiconductors, equipment for their production, and derivative products from China. The measure aims to paralyze Chinese technological progression and force the re-shoring of the American industrial base.

  • 100% Pharmaceutical Tariffs (April 2, 2026): Implementation of 100% ad valorem duties on imports of patented pharmaceutical products and essential ingredients from China, striking a key sector for Beijing's exports.

  • Section 301 Review (May 6, 2026): The Office of the United States Trade Representative (USTR) officially launched the second statutory four-year review of the 2018 tariffs on Chinese products. American domestic industries can request their continuation by summer 2026, securing the permanence of these tariff barriers.

  • Critical Minerals Strategy (January 14, 2026): The Department of Commerce (DOC) initiated investigations and actions under Section 232 to target the Chinese monopoly on processed minerals necessary for defense and advanced manufacturing, threatening new import restrictions.


Outlook for the Summit: A Systemic "Compliance Trap"

The summit opens with officials from both sides ready to use regulatory authorities as weapons of pressure. Treasury Secretary Scott Bessent has called China's maneuvers a "provocation" aimed at chilling global supply chains, while Secretary of State Marco Rubio has already announced secondary sanctions against anyone operating under the protection of the Chinese "blocking statute."

For multinationals, uncertainty is at its peak. They find themselves in a "legal pincer": obeying American diversification measures means risking civil and administrative retaliation in China; ignoring them means ending up in the crosshairs of Washington’s secondary sanctions. The Trump-Xi summit is unlikely to resolve these tensions, focusing instead on the containment of a conflict where regulatory sovereignty has replaced trade volumes as the primary battleground of national security.

Commenti


©2020 di extrema ratio. Creato con Wix.com

bottom of page